Health and Healthcare
Savient's New Gout Treatment Hits Targets (SVNT)
Published:
Last Updated:
Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is seeing its shares surging in pre-market trading. The company showed statistically significant positive results for the Puricase Phase III study in treatment-failure of gout patients. Puricase’s 8mg dosage administered by a two-hour intravenous infusion every two weeks or every four weeks met Savient’s primary efficacy endpoint.
Savient also said it plans to file for approval with the FDA in 2008 based on the positive results from these Phase III trials. If you will recall, this was Jim Cramer’s #1 SPECULATIVE STOCK FOR 2007.
Shares closed yesterday at $14.46, and the 52-week trading range had been $10.58 to $15.75. It now looks like it is trading at a new all-time high of $20.95 in pre-market activity.
Jon C. Ogg
December 13, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
